Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 14,705,008	$ 20,318,411
Accounts receivable trade, net of allowance of $0 at December 31, 2016 and 2015, respectively	2,891,723	2,566,101
Deferred costs	3,582,298	2,911,743
Prepaid and other current assets	3,469,932	3,476,177
Total current assets	24,648,961	29,272,432
Property, plant and equipment, net	17,149,241	17,064,900
Goodwill	7,013,315	7,013,315
Intangible assets, net	2,307,880	2,877,880
Other assets	713,451	976,768
Total assets	51,832,848	57,205,295
Current Liabilities
Accounts payable	4,366,753	4,107,388
Accrued liabilities	6,062,569	6,198,488
Long-term debt, current	3,126,457	4,171,456
Notes payable, current	847,327	1,192,666
Unearned revenues, current	5,098,193	5,345,225
Total current liabilities	19,501,299	21,015,223
Deferred income taxes	1,070,700	932,662
Notes payable	292,217	583,041
Unearned revenues, long-term	4,587,397	0
Long term debt	2,524,897	10,828,544
Other long-term liabilities	389,858	562,001
Total liabilities	28,366,368	33,921,471
Commitments and Contingencies
Redeemable Securities - Non-Controlling Interests	19,400,000	0
Stockholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2016 and December 31, 2015	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 8,205,791 and 5,673,302 shares, at December 31, 2016 and December 31, 2015, respectively	8,206	5,673
Additional paid-in capital	410,372,049	396,547,401
Treasury stock, at cost; 11,080 shares at December 31, 2016 and December 31, 2015 respectively	(707,637)	(707,637)
Accumulated deficit	(404,788,809)	(372,132,490)
Accumulated other comprehensive income	0	486
Total Caladrius Biosciences, Inc. stockholders' equity	4,883,909	23,713,533
Noncontrolling interests	(817,429)	(429,709)
Total equity	4,066,480	23,283,824
Liabilities and Equity, Total	$ 51,832,848	$ 57,205,295

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Name:	us-gaap_AccountsPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3-4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3
-Subparagraph a(1)
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 4
-Article 5